![]() The primary objective was to compare the association between HER2-E subtype (versus others) and pCR. Here, we present a meta-analysis to validate the association of the HER2-E subtype with pCR following anti-HER2-based neoadjuvant treatments with or without chemotherapy (CT).Ī systematic literature search was performed in February 2019. Among these, the HER2-Enriched (HER2-E) appear to be associated with higher pathological complete response (pCR) rates following anti-HER2-based regimens. Electronic address: (HER2+) breast cancer (BC) comprises all the four PAM50 molecular subtypes. 20 Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain SOLTI Breast Cancer Research Group, Barcelona, Spain Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.19 Department of Medicine, University of North Carolina, Chapel Hill, USA.18 SOLTI Breast Cancer Research Group, Barcelona, Spain Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Department of Medical Oncology, Institut Català d'Oncologia-H.17 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA Department of Medicine, Baylor College of Medicine, Houston, TX, USA.16 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.15 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA Department of Medicine, Baylor College of Medicine, Houston, TX, USA Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.14 Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.13 SOLTI Breast Cancer Research Group, Barcelona, Spain.12 Department of Pathology, Hospital Clinic, Barcelona, Spain. ![]() 11 Novartis Pharma AG, Basel, Switzerland.10 Department of Neuroscience, Reproductive Medicine, Odontostomatology, University of Naples Federico II, Naples, Italy.9 Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy Division of Medical Oncology 2, Istituto Oncologico Veneto - IRCCSS, Padova, Italy.8 Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Milan, Italy.7 Department of Genetics, University of North Carolina, Chapel Hill, USA.6 Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.5 Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.4 SOLTI Breast Cancer Research Group, Barcelona, Spain Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.3 Department of Medical Oncology, Ospedale Policlinico San Martino, University of Genova, Genova, Italy.2 Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain SOLTI Breast Cancer Research Group, Barcelona, Spain Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.1 Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain SOLTI Breast Cancer Research Group, Barcelona, Spain.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |